All Professionals
Overview
Jessica Montes is an associate in the Litigation practice of Paul Hastings and is based in the firm's New York office. Her practice focuses on internal and government investigations, white collar defense, and compliance counseling, with an emphasis on fraud and abuse and anti-bribery and anti-corruption.
Ms. Montes received her law degree from Columbia Law School, where she served on the Columbia Journal of Gender and Law. She earned Bachelor of Arts degrees in Political Science and International Studies from the University of California, Irvine, where she graduated with honors. Ms. Montes is admitted to practice law in New York.
Representations
Internal and Government Investigations
- Representation of in vitro diagnostic testing company in connection with Federal and state inquiries related to potential violations of U.S. and state kickback, false claim, and Stark law statutes
- Representation of mulltinational rolling stock manufacturer before the DOJ and South African regulators involving alleged violations of the U.S. FCPA and local corruption and money laundering statutes
- Representation of multi-national medical device manufacturer in connection with a voluntary disclosure to the U.S. Department of Justice related to potential violations of the Foreign Corrupt Practices Act in China and various other jurisdictions
- Representation of multi-national rare disease pharmaceutical company in connection with an investigation into potential violations of the Foreign Corrupt Practices Act in Europe, Japan, and Latin America by the U.S. Department of Justice and Securities and Exchange Commission
- Representation of pharmaceutical company in connection with a U.S. Department of Justice subpoena and investigation into its patient support program, drug pricing, and specialty pharmacy relationships
- Representation of pharmaceutical company in connection with a U.S. Department of Justice subpoena and investigation into manufacturer rebates to pharmacy benefit managers
- Representation of a senior executive of a biopharmaceutical company in connection with a U.S. Department of Justice subpoena and investigation into donations to copay assistance charities
- Representation of an opioid manufacturer in connection with a multi-district federal investigation and a qui tam complaint focusing on promotional practices and alleging potential violations of the anti-kickback statute and False Claims Act, resulting in a $7.55 million civil-only settlement in the District of New Jersey
- Conducted internal investigation on behalf of a pharmaceutical company into whistleblower allegations of potential Anti-Kickback Statute violations related to company-sponsored clinical trials, investigator-initiated studies, and advisory boards
- Conducted internal investigation on behalf of a pharmaceutical company into allegations of pre-approval promotion, off label promotion, and other improper sales and marketing practices
Risk Assessments and Diligence
- Conducted global anti-bribery and anti-corruption compliance program assessment on behalf of multi-national pharmaceutical company
- Conducted proactive compliance market reviews on behalf of multinational pharmaceutical company in European markets
- Conducted anti-bribery and anti-corruption diligence on high-risk distributors in the Middle East, Asia-Pacific, and Latin America
- Conducted proactive compliance reviews of manufacturer patient support and assistance programs in view of U.S regulator guidance and enforcement on behalf of Fortune 100 pharmaceutical company
Compliance Counseling
- Enhanced and implemented global anti-bribery and anti-corruption compliance programs on behalf of multinational pharmaceutical and medical device companies
- Developed and implemented numerous corporate policies and procedures addressing interactions with healthcare professionals in the U.S. and abroad and due diligence and risk management of third parties
insights
- Recent Whistleblower Activity Increases Pressure on Internal Reporting and Investigation Mechanisms - August 15th, 2023
- France’s New Anti-Benefits Regime: Core Framework and Key Takeaways - October 22nd, 2020
- Key Takeaways From the Novartis 345 Million Dollar FCPA Settlement - July 1st, 2020
- The Trend Continues: As Outward Bound Investments from Japanese Multinationals Continue to Grow, So Do ABAC Compliance and Other Enforcement Risks - June 24th, 2020
- Part II of II—Not a U.S.-Fits-All-Proposition: Four Key Considerations When Building the Compliance Framework to Go Global with Patient Support - April 17th, 2019
- Part I of II—Not a U.S.-Fits-All-Proposition: Four Key Considerations When Building the Compliance Framework to Go Global with Patient Support - April 11th, 2019
- Another Life Sciences Company Announces a Multi-Million Dollar Settlement in the U.S. Department of Justice’s Relentless Pursuit of Donations to Copay Assistance Charities - June 19th, 2018
- In Light of Digital Realty and the Largest Ever Dodd-Frank Whistleblower Award, Whistleblower Risks Are Up and Company Compliance Programs Are Under Pressure - April 19th, 2018
- Growth Opportunities Come With Danger: As Japanese Life Sciences Companies’ Outward Bound Investments Continue to Grow, So Do the Significant Compliance - December 9th, 2016